Antiallergic activity of H-receptor antagonists assessed by nasal challenge

Bousquet, Jean; Lebel, B.; Chanal, I.; Morel, A; Michel, François‐Bernard

doi:10.1016/0091-6749(88)90094-2

Cited by 109 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many of the newer, non-sedating agents also possess certain ''anti-allergic'' properties which may have a more profound effect on allergic inflammation (8). As a class, they display avid binding to the H 1 receptor and have a quick onset of action.…”

Section: Management Strategiesmentioning

confidence: 99%

Allergic Rhinoconjunctivitis – An Overview

Katelaris

2000

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

Section: Management Strategiesmentioning

confidence: 99%

Allergic Rhinoconjunctivitis – An Overview

Katelaris

2000

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

“…Loratadine also has demonstrated antiallergic activity, as shown by the drug's inhibition of the release of histamine as well as the production and re lease of prostaglandins (PGD2) and leukotricncs (LTC4) from mast cells [7,8,20,22,23]. Further, Loratadine has been reported in both animal models and in humans to protect against several allergic challenges, such as skin prick tests, nasal and bronchial challenges [7,8,20,22,23].…”

Section: Introductionmentioning

confidence: 99%

“…The conjunctival provocation test (CPT) is a safe, re liable and reproducible model to investigate the patho physiology of allergic diseases [1-51 and, consequently, to assess the pharmacologic modulation of the allergic re sponse [6][7][8][9], CPT evaluation may be performed by clinical examination, cytological evaluation and/or analysis of mediator release in the lacrimal fluid [10][11][12]. As demon strated in previous studies, exposure of the conjunctival mucosa to a specific allergen results in an immediate hy persensitivity reaction occurring 20-30 min after challenge and quickly subsiding in sensitized individuals [13,14].…”

Section: Introductionmentioning

confidence: 99%

Protective Effect of Loratadine on Late Phase Reaction Induced by Conjunctival Provocation Test

Ciprandi

Buscaglia

Marchesi³

et al. 1993

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The protective effect of Loratadine, a new generation, non-sedating antihistamine, on clinical and cellular events during the early phase reaction (EPR) and late phase reaction (LPR) of the allergen-specific conjunctival provocation test (CPT) was assessed out of the pollen season in 20 seasonally allergic rhino-conjunctivitis patients. After a screening CPT, selected patients were randomized to Loratadine (10 mg OD) or matching placebo for 7 days. CPT was repeated following treatment. Clinical and cellular responses were evaluated by a symptom score and cell counting in conjunctival scrapings before, and 30 min and 6 h after challenge with allergen (one eye) or placebo (control eye). Conjunctival symptom severity following CPT was reduced at 30 min (EPR) and 6 h (LPR) after CPT in the Loratadine group compared to placebo group (p < 0.01), as was the total number of inflammatory cells (p < 0.001). In conclusion, Loratadine protects against the clinical and cellular EPR and LPR events consequent to CPT, showing antiallergic properties.

show abstract

“…We have reported that terfenadine significantly inhibited anti-IgE-induced histamine release from human basophils and calciumionophore-induced leukotriene C4 production from hu man eosinophils [16]. Bousquet et al [22] reported that terfenadine attenuated histamine release and prostaglan din D2 in nasal secretions. Tasaka et al [23] reported a suppressive effect of terfenadine on histamine release from peritoneal mast cells of rats.…”

mentioning

confidence: 99%

Effect of Terfenadine on Neutrophil and Eosinophil Chemotactic Activities after Inhalation of Platelet-Activating Factor in vivo and on Neutrophil Chemotaxis in vitro

Okada

Hopp

Miyagawa

et al. 1992

Int Arch Allergy Immunol

View full text Add to dashboard Cite

In this double-blind crossover study we evaluated the effect of terfenadine on the rise in neutrophil chemotactic activity (NCA) and eosinophil chemotactic activity (ECA) in serum induced by platelet-activating factor (PAF) inhalation in 8 asthmatics. Additionally, we examined the direct effect of terfenadine on neutrophil chemotaxis in vitro in 7 allergic subjects. NCA and ECA in serum after PAF inhalation and neutrophil chemotaxis were measured using a modified Boyden chamber method. An initial elevation of NCA after PAF inhalation was inhibited by terfenadine, but the effect was diminished after subsequent PAF inhalations. Terfenadine showed no effect on ECA. In vitro PAF- and fMLP-induced neutrophil chemotaxis were significantly inhibited by terfenadine. These results suggest that terfenadine may have antiallergic properties in addition to its H₁ receptor blockade.

show abstract

Antiallergic activity of H-receptor antagonists assessed by nasal challenge

Cited by 109 publications

References 27 publications

Allergic Rhinoconjunctivitis – An Overview

Allergic Rhinoconjunctivitis – An Overview

Protective Effect of Loratadine on Late Phase Reaction Induced by Conjunctival Provocation Test

Effect of Terfenadine on Neutrophil and Eosinophil Chemotactic Activities after Inhalation of Platelet-Activating Factor in vivo and on Neutrophil Chemotaxis in vitro

Contact Info

Product

Resources

About